1-3 of 3
Finn Wislöff
Close
Sort by
Journal Articles

A Phase II Study of PXD101 in Advanced Multiple Myeloma.

Daniel Sullivan, MD, Seema Singhal, MD, Michael Schuster, MD, James Berenson, MD, Peter Gimsing, MD, Finn Wislöff, MD, Anders Waage, MD, Melissa Alsina, MD, Robert Gerwien, PhD, Anne Clarke, RN, MPH, Karen Moller, Chean Eng Ooi, PhD
Journal: Blood
Blood (2006) 108 (11): 3583.
https://doi.org/10.1182/blood.V108.11.3583.3583
Published: 2006
Journal Articles

Intensive Therapy in Multiple Myeloma. Long-Term Follow-Up with Focus on Relapse after Transplantation. The Nordic Myeloma Study Group (NMSG).

Stig Lenhoff, MD, Martin Hjorth, MD, Johan Lanng Nielsen, MD, Ingemar Turesson, MD, Finn Wislöff, MD, Jan Westin, MD
Journal: Blood
Blood (2004) 104 (11): 938.
https://doi.org/10.1182/blood.V104.11.938.938
Published: 2004
Journal Articles

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study

Stig Lenhoff, Martin Hjorth, Erik Holmberg, Ingemar Turesson, Jan Westin, Johan Lanng Nielsen, Finn Wislöff, Lorentz Brinch, Kristina Carlson, Margaretha Carlsson, Inger-Marie Dahl, Peter Gimsing, Erik Hippe, Hans E. Johnsen, Jon Lamvik, Eva Löfvenberg, Ingerid Nesthus, Stig Rödjer
Journal: Blood
Blood (2000) 95 (1): 7–11.
https://doi.org/10.1182/blood.V95.1.7
Published: 2000